Abstract：
B cell acute lymphoblastic leukemia (B-ALL) is the most prevalent pediatric cancer. MicroRNAs (miRNAs) are 18-22nt non-coding transcripts shown to be essential for the development of many cancers. While some miRNAs are reportedly expressed differentially between healthy and B-ALL, no studies have reported a consensus miRNA signature. Therefore, we performed a reanalysis of five miRNA datasets to identify differentially expressed miRNAs (DEmiRs) and a meta-analysis of previously identified DEmiRs from 25 studies. Overall, the re-analysis showed that the DEmiR data clustered by platform and not by disease state. The meta-analysis also did not reveal a consensus miRNA signature as there were many miRNAs upregulated in some studies and downregulated in others. However, eight promising miRNAs (miR-181b, miR-128b, miR-181a, miR-128, miR-128a, miR-181c, miR-155, miR-142-3p, and miR-451) were identified from the meta-analysis, which could be the basis of future investigations. These analyses reveal that standardization of miRNA isolation and analysis is needed in B-ALL to enable cross-study comparisons and identify a consensus signature.
摘要：
B细胞急性淋巴细胞白血病（B-ALL）是最常见的儿科癌症。MicroRNAs（miRNA）是18-22nt非编码转录本，对许多癌症的发展至关重要。虽然据报道一些miRNA在健康和B-ALL之间差异表达，尚无研究报告共有miRNA特征.因此,我们对5个miRNA数据集进行了重新分析,以鉴定差异表达的miRNA(DEmiRs),并对来自25项研究的先前鉴定的DEmiRs进行了荟萃分析.总的来说,重新分析显示,DEmiR数据按平台而非疾病状态进行聚类.荟萃分析也没有揭示一致的miRNA特征,因为在一些研究中存在许多miRNA上调而在其他研究中存在许多miRNA下调。然而,八个有前途的miRNA(miR-181b，miR-128b,miR-181a,miR-128,miR-128a,miR-181c,miR-155,miR-142-3p,和miR-451）从荟萃分析中鉴定，这可能是未来调查的基础。这些分析揭示,在B-ALL中需要miRNA分离和分析的标准化,以实现跨研究比较和鉴定共有签名。
